ArticleMalaria journal2026
Prevalence of molecular markers related to artemisinin partial resistance and ACT partner drug resistance in the Plasmodium falciparum population in Kongo Central, DRC.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundArtemisinin-based combination therapies (ACTs) are the cornerstone of Plasmodium falciparum malaria treatment. Recent reports have documented P. falciparum with mutations associated with artemisinin partial resistance in eastern DRC, raising concerns about reduced drug susceptibility. This study examines the prevalence of mutations linked to reduced ACT efficacy in P. falciparum isolates collected December 2024-February 2025 in the Kongo Central Province, western DRC.
methodDried blood spots were obtained from children under two years of age attending targeted health facilities and testing positive for malaria with rapid diagnostic tests. Diagnosis was confirmed with qPCR and Illumina-targeted amplicon sequencing was used to analyse mutations in the pfk13, pfubp-1, pfcoronin, pfmdr-1 and pfcrt genes.
resultsPfk13 Q613E classified by WHO as potential marker of artemisinin partial resistance was found in a single sample, while pfubp-1 mutations D1525E and E1528D, also suspected of being linked to artemisinin partial resistance were found in 20% and 22% of the sequencing positive samples, respectively. N-Y-S-N-D and N-F-S-N-D were the dominating pfmdr1 haplotypes while the pfcrt wildtype C-V-M-N-K haplotype was highly dominant as well (90%).
conclusionOur results suggest no immediate concern of maintaining artemisinin and ACTs as first-in-line treatment for malaria in Kongo Central, DRC. However, the findings are of concern and continued molecular surveillance is needed to monitor emerging resistance patterns and allow for a timely response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.